Myofibrillogenesis regulator-1 (MR-1) is a novel homologous gene, identified from a human skeletal muscle cDNA library, that interacts with contractile proteins and exists in human myocardial myofibrils. The present study investigated MR-1 protein expression in hypertrophied myocardium and MR-1 involvement in cardiac hypertrophy. Cardiac hypertrophy was induced by abdominal aortic stenosis (AAS) in Sprague-Dawley rats. Left ventricular (LV) hypertrophy was assessed by the ratio of LV wet weight to whole heart weight (LV/HW) or LV weight to body weight (LV/BW). Rat MR-1 (rMR-1) expression in the myocardium was detected by immunohistochemical and Western blotting analysis. Hypertrophy was induced by ANG II incubation in cultured neonatal rat cardiomyocytes. The effect of rMR-1 RNA interference on ANG II-induced hypertrophy was studied by transfection of cardiomyocytes with an RNA interference plasmid, pSi-1, which targets rMR-1. Hypertrophy in cardiomyocytes was assessed by [ 3 H]Leu incorporation and myocyte size. rMR-1 protein expression in cardiomyocytes was detected by Western blotting. We found that AAS resulted in a significant increase in LV/HW and LV/BW: 89% and 86%, respectively (P Ͻ 0.01). Immunohistochemistry and Western blot analysis demonstrated upregulated rMR-1 protein expression in hypertrophic myocardium. ANG II induced a 24% increase in [ 3 H]Leu incorporation and a 65.8% increase in cell size compared with control cardiomyocytes (P Ͻ 0.01), which was prevented by treatment with losartan, an angiotensin (AT 1) receptor inhibitor, or transfection with pSi-1. rMR-1 expression increased in ANG II-induced hypertrophied cardiomyocytes, and pSi-1 transfection abolished the upregulation. These findings suggest that MR-1 is associated with cardiac hypertrophy in rats in vivo and in vitro. RNA interference; left ventricle; cardiac hypertrophy; cardiac remodeling CARDIAC HYPERTROPHY is an early milestone over the clinical course of heart failure and an important adaptive mechanism that occurs as a result of various mechanical, hemodynamic, hormonal, and pathological stimuli (19). The heart adapts to increased demands for cardiac work by increasing muscle mass through initiation of a hypertrophic response. However, left ventricular (LV) hypertrophy is a risk factor for congestive heart failure and sudden death. Because cardiac hypertrophy is a highly complex disorder that results from a combination of genetic, physiological, and environmental factors, one of the key events in its pathogenesis and treatment is genetic mutation of contractile proteins (16). The discovery and functional clarification of cardiac hypertrophy-related novel human genes are important for understanding the molecular mechanisms of cardiac hypertrophy. There is still a broad gap, however, between identifying the defective gene and understanding how this defect leads to the cardiac abnormalities.Recently, we identified a novel homologous gene, myofibrillogenesis regulator-1 (MR-1), from a human skeletal muscle cDNA library (10). The MR...